CV Sciences (CVSI) Share-based Compensation (2011 - 2026)
CV Sciences (CVSI) reported Share-based Compensation of $1.1 million for Q1 2026, up 832.2% on a YoY basis from $118000.0 in Q1 2025, and up 794.31% sequentially from $123000.0 in Q4 2025.
CV Sciences (CVSI) Share-based Compensation (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 14 years of Share-based Compensation data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 832.2% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 285.96% YoY), and the FY2025 full-year result was $700000.0, changed 0.0% from the prior year.
- Share-based Compensation rose to $1.1 million in Q1 2026, from $123000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q1 2026 to a low of -$171000.0 in Q2 2022.
- A 5-year average of $381375.0 and a median of $120500.0 in 2023 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation tumbled 118.75% in 2022 and soared 2471.43% in 2024, its largest moves.
- Tracing CVSI's Share-based Compensation over 5 years: stood at $664000.0 in 2022, then plunged by 95.03% to $33000.0 in 2023, then soared by 215.15% to $104000.0 in 2024, then rose by 18.27% to $123000.0 in 2025, then jumped by 794.31% to $1.1 million in 2026.
- Business Quant data shows CVSI's Share-based Compensation at $1.1 million in Q1 2026, $123000.0 in Q4 2025, and $800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 123,000.00 |
| Dec 31, 2025 | 123,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 900,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | 104,000.00 |
| Dec 31, 2024 | 104,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Jun 30, 2024 | 900,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 33,000.00 |
| Dec 31, 2023 | 33,000.00 |